A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

NCT02152371 · Completed

Last updated 2026-05-28

This clinical trial tests the medication dulaglutide in adults with type 2 diabetes to see how it affects blood sugar levels over 28 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 300 people

Who can join Ages 18+ · all sexes

Timeline Started 2014-05 · est. completion 2015-10

Where 40 sites · Czechia, Hungary, Italy, Puerto Rico, Spain, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02152371 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SQ
Placebo Drug

Administered SQ
Insulin Glargine Drug

Administered SQ
Metformin Drug

Administered orally

Main thing measured	Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02152371 ↗